12,372 trials
Diabetic Peripheral Neuropathy
Primary: Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)…
Acne
Primary: Acne Lesion Percent Reduction — -54.3; -35; -53.5 percent reduction of number of lesions
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Adverse Events — 86.0; 91.3 percentage of patients with TEAE
Femur Neck Fracture
Primary: Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture — 74; 93 Percentage of participants
HIV Infections · Pneumococcal Infections
Primary: Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All…
Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 437.0; 751.0 Days — p=<0.001
Femur Neck Fracture
Primary: Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture — 87; 86 percentage of participants
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication — 89.4; 86.2 percentage of responders
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough Forced Expiratory Volume at 1 Second (FEV1) — 1.499; 1.436 Liters
Allergic Rhinitis
Primary: Number of Participants Experiencing at Least One Adverse Event (AE) — 6; 2 participants
Kawasaki Disease
Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…
Branch Retinal Vein Occlusion
Primary: Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF — 24; 48 participants — p=0.0003
Breast Cancer · Diagnostic Imaging
Primary: Difference for Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader — 46.6; 30.8; 23.3; 17.8 difference in sensitivity (%)
Breast Cancer
Primary: Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader — 15.2; 31.9; 30.4; 15.9 difference in sensitivity (%)
Type 2 Diabetes Mellitus
Primary: Increased HDL-Cholesterol and Decreased Triglycerides — 7.9; 2.7; 15.7; -1.5 % Change — p=0.05